Tekcapital Share Discussion Threads

[volsung] 26/6/2019 12:01

Liking the look of that chart

[hazl] 26/6/2019 09:53

FDA approval makes an incredible difference.
Just look at IQAI's recent rises just on the whisper of it .
And they haven't necessarily been approved.

[hazl] 26/6/2019 09:51

As ever somebody that doesn't understand good prospects.

[pjj71] 26/6/2019 09:48

more dilution of their stake.. how much more will need to be sold down b4 any cash comes through the door... although i would concur the eventual prospects look better than their foray into musical glasses...

[hpcg] 26/6/2019 08:35

FDA approval is like phase 3 success for a drug; the private valuation of Belluscura will sky rocket.

[ewanwhose] 26/6/2019 08:21

Don't want to p on the parade, but the TEK results in Feb specified 'Q3 2019' for FDA approval. Now only saying '2019' implies (to a suspicious person such as myself) that it has slipped.Bellascura website says commercialisation Q4 2020 so likely to need more investment before becoming cash positive.Still like Bellascura and TEK.

[hazl] 26/6/2019 07:07

NOW THAT'S REALLY great news!

Belluscura FDA approval likely this year!

[someuwin] 26/6/2019 07:06

26 June 2019

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

Portfolio Company Update: Belluscura plc

On track to likely receive FDA clearance later this year

Tekcapital Plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is pleased to announce that its portfolio company Belluscura plc has received commitments for GBP725,000 of additional funding at 15p/share and is on track to receive FDA clearance later this year followed by commercial launch in H1 2020.

The Product

Belluscura has developed a patented portable oxygen concentrator called the X-PLOR, that can deliver 96% pure oxygen to patients 24/7. According to the Company(1) , the X-PLOR is designed to replace metal oxygen tanks and heavier devices. Weighing only 1.4kg, X-PLOR is 33% lighter and research suggests can provide 37% more oxygen per kg than leading competitors. X-PLOR is portable, increasing the mobility of people suffering from COPD and price efficient, costing less than tanks over the duration of the disease, and is upgradeable with user replaceable filters, so as the disease progresses, there is no need to buy another expensive higher capacity device, rather just change the filter as the prescription changes. Belluscura has exclusively licensed, acquired or filed 13 patents and applications in the field of concentrated oxygen generation and has a robust pipeline with additional oxygen enrichment products planned for release in 2020.

Market Information

Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease. Over 250 million people worldwide suffer from COPD(2) . COPD is not curable, but patients with COPD are prescribed supplemental oxygen to help relieve shortness of breath and reduce the risk of death. According to the British Lung Foundation, in the U.K. an estimated 1.2 million people are living with diagnosed COPD.(3) Globally, the medical portable O(2) concentrator market is expected to grow from $1.4bn in 2018 to $2.4bn by 2024, with a CAGR of 9%.(4)

Dr Clifford Gross, Chairman at Tekcapital commented,

"We are delighted to see that Belluscura has strengthened its balance sheet and is on track to likely receive FDA clearance later this year. The fundraise was conducted at 15p per share, a 50% uplift over the valuation Tekcapital listed for Belluscura in its 2018 Annual Accounts. The Directors believe that Belluscura's new device will help to improve the quality of life and reduce treatment cost for individuals suffering from COPD."

Tekcapital owns approximately 21.7% (9.3m shares) of Belluscura plc.

About Belluscura plc

Belluscura plc is an English company that is focused on improving healthcare and people's lives by developing new and innovative treatment platforms. They license and develop proprietary technologies that can be applied across a range of treatment possibilities. To learn more please visit www.belluscura.com.

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed intellectual properties and provides a range of IP investment services to make it easy for organisations to commercialise university-developed technology. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

[hazl] 25/6/2019 16:02

Meanwhile TEK tries to improve the lives of people by reducing their salt intake.

[hazl] 25/6/2019 15:55

OT FOR PJJ
not anything to with TEK I might add



hazl
31 May '17 - 10:08 - 830 of 1206 Edit
0 0 0
I personally couldn't invest in a company that sells cell-lines like

HEK 293 .

[thomstar] 25/6/2019 15:52

Classic tree shake

[hazl] 25/6/2019 15:44

You might even find a post from me on the bb if you care about such things.
I haven't touched Coca Cola either since.
The cell lines that are readily for sale have quite frequently come from foetal cells.
Liver cells are used by Coca Cola as taste receptors apparently.
What about the rights of the unborn?
For such a trite commercial use as well.

[hazl] 25/6/2019 15:34

hzd I dismissed for my own ethical reasons....I looked into them years ago thinking I might buy in.
Do you know how they originally source their products?

[pjj71] 25/6/2019 14:43

not at all.. hzd a great company... and no losses there for me (at the mo)...

those glasses get bad reviews on youtube... should have gone to spec savers ;))

[hazl] 25/6/2019 13:45

Ah but is that taking into account your losses at HZD?
No thought not .


Fancy holding a Woodford stock at the moment.
Perhaps you do need those glasses...a bit short-sighted wasn't it?!

[pjj71] 25/6/2019 13:09

those glasses.. might by a pair with my short profits... not...

[ntv] 25/6/2019 12:44

who wants a sky full of hornet like drones delivering parcels
The US might but the enviromental impact on birds and the plant will be awfu;

[hazl] 25/6/2019 11:24

Why don't you pass then?
Good posts from some above plenty to look forward to.


IMO

[letmepass] 25/6/2019 11:11

Looking like a funding issue here.. 5p coming

[sexylinda] 25/6/2019 10:03

Don't look it purely in intraday terms; 10% down today but 109.3% up over 3 months, 87.5% up YTD. [

Today's news is good, the team leading Guident is very very experienced. We just have to await further commercial news.

Salarius on its own, IMO, is worth more than TEK's market cap now that sales are kicking off.

I'm not too convinced about Lucyd but again let's await more news.

[pjj71] 25/6/2019 09:12

Well -10% a day looks painful to me

[29palms] 25/6/2019 08:58

"lots of pain for current shareholders today...."

LOL, LOL

YTD share price performance on a bid basis = +75%

As always,
DYOR

[hazl] 25/6/2019 07:45

Ha ha an envious detractor already!

[dave4545] 25/6/2019 07:40

More positive news

[pjj71] 25/6/2019 07:24

Why so much cash burn and have they got through that last confetti placing yet ?? Just trying to assess whether this remains plenty of Jam tomorrow but lots of pain for current shareholders today....